Current Controversies in Oncology

Current Controversies in Oncology and Current Insights in Oncology articles provide a forum for the exchange of views on topical issues in the field of oncology. The opinions expressed are those of the authors alone. They do not necessarily reflect the views of the Editor or ASCO.

Jun 30, 2015
Each year, over 1.6 million Americans and 14 million people worldwide are diagnosed with cancer. Further, cancer causes the deaths of 600,000 people annually in the United States and over eight million people globally. It is estimated that only 5% to 10%...
Apr 22, 2015
In this edition of Current Controversies in Oncology, expert hepatobiliary surgical oncologists debate the added benefit of neoadjuvant therapy for resectable hepatic colorectal metastases. While few would downplay the option of systemic therapy for a patient with bilobar metastases....
Feb 24, 2015
Jeff P. Sharman, MD, on why traditional chemoimmunotherapy with FCR should still be considered for ongoing use as an effective therapy: “If a fit younger patient has a favorable risk profile, intense chemoimmunotherapy may be the best route for long-term disease control—and possibly cure.”
Dec 14, 2014
"As you can surmise from the articles by Dr. Mark Moyad and Dr. L. Michael Glodé, one thing we can say with certainty is that dietary supplements are mired in controversy."
Oct 24, 2014
"Induction chemotherapy may theoretically enhance treatment outcomes  . . . by decreasing tumor volume, and therefore the fraction of hypoxic cells that contribute to radioresistance; by bringing about chemosensitization, particularly in combination with platins and . . ."
Aug 26, 2014
"There is overwhelming evidence that RARP is associated with decreased blood loss, lower transfusion rates, and shorter length of hospital stay."
 
Jun 19, 2014
"Another major advantage of PET is its ability to detect distant metastasis in organs outside the central nervous system when CT is negative."
Apr 22, 2014
"As oncologists, we painstakingly translate clinical evidence for our patients. We inform them of odds, percentages, risks, and survival. When it comes to deciding on a treatment path, we lean heavily on the potential of physical toxicity, as we should, but are we missing . . ."
Feb 25, 2014
"The availability of more effective combination chemotherapy regimens is transformative and potentially lays the foundation for greater benefit with chemoradiation. We need to figure this out."
 
Dec 16, 2013
"Given the possibility of using highly effective anti-androgen treatment . . . with new agents and the promise hinted at by sipuleucel-T and fowlpox-PSA-TRICOM vaccine, it should be possible to contemplate cure of metastatic prostate cancer within the next decade."

Pages